|Bid||6.75 x 900|
|Ask||8.20 x 800|
|Day's Range||6.97 - 7.19|
|52 Week Range||5.48 - 23.99|
|Beta (3Y Monthly)||2.06|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
President Donald Trump celebrated the dismissal of a lawsuit related to his private companies on Wednesday, as he signed an executive order directing the government to revamp the nation’s care for kidney disease.
Shares of DaVita Inc. bounced 4.3% in afternoon trading Wednesday, after President Trump signed an executive order on kidney disease, aimed at cutting costs of dialysis treatments. The stock had tumbled 9.8% over the past two sessions in anticipation of the executive order. DaVita said late Tuesday that the Trump administration's initiatives are expected to support DaVita's investments to prevent kidney disease, encourage home kidney care and improve kidney transplantation rates. "We've been investing in capabilities to deliver holistic care that addresses our patients' needs beyond kidney disease, such as mental health, social services and nutrition," said Chief Executive Javier Rodriguez. "We will continue to work with the Administration and Congress to launch programs that address broader care opportunities." Shares of fellow dialysis services provider American Renal Associates Holdings Inc. rsoe 1.6%, after plunging 9.6% on Tuesday. Year to date, DaVita's stock has gained 6.8% and American Renal shares have plummeted 40.6%, while the SPDR Health Care Select Sector ETF has tacked on 8.1% and the S&P 500 has advanced 19.5%.
Traders flee after the company announces that its CFO has resigned and that some of its financial statements need to be restated. Here's what investors need to know.
American Renal Associates (ARA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
American Renal Associates (ARA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Today we'll evaluate American Renal Associates Holdings, Inc. (NYSE:ARA) to determine whether it could have potential as an investment idea. Specifically, we'll consider its Return On Capital Employed (ROCE), since Read More...
American Renal Associates (ARA) delivered earnings and revenue surprises of 46.15% and -2.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Beverly, Massachusetts-based company said it had profit of 6 cents. Earnings, adjusted for non-recurring costs, came to 19 cents per share. The dialysis centers owner posted revenue ...
American Renal Associates (ARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aramus SA (WSE:ARA) is a small-cap stock with a market capitalization of zł7.1m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...